【摘要】 基于肿瘤和正常组织基因差异表达开发的靶向药在临床上获得巨大成功。A型红细胞生成素肝配蛋白受体2 (EphA2)在多种人类肿瘤中高表达，发挥驱动肿瘤增殖、迁移和侵袭的癌基因功能，有作为肿瘤治疗靶点的潜力。靶向EphA2可有效抑制肿瘤生长，并恢复耐药肿瘤细胞对药物的敏感性。该文详细介绍了EphA2靶点结构和双向调控信号的机制，深入探讨了不同途径在其靶向治疗中的优势和复杂性，概述了EphA2靶向治疗的最新临床前进展，以及未来临床应用的潜力。更多还原

【Abstract】 Targeted drugs developed based on the differential gene expression between cancerous and normal tissues have achieved significant success in clinical settings. Erythropoietin-producing hepatocellular receptor A2(EphA2)has been found to be highly expressed in various human tumors, and plays a role as an oncogene driving tumor proliferation, migration, and invasion, making it a promising therapeutic target for cancer treatment. Targeting EphA2 can effectively inhibit tumor growth and restore drug sensitivity in drug-resistant tumor cells. This review provided a detailed overview of the mechanisms underlying EphA2 targeting, including its target structure and bidirectional regulatory signals, and investigated the advantages and complexities of strategies targeting EphA2through canonical and noncanonical signaling pathways. Furthermore, it summarized the latest preclinical advancements in EphA2-targeted therapy and discussed its potential for future clinical applications.更多还原